Trials / Recruiting
RecruitingNCT06511141
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Sacral Neuromodulation for Male Overactive Bladder
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Axonics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Detailed description
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients who have a prior history of radical prostatectomy or radiation for prostate cancer or who have a history of cytoreductive surgical intervention for benign prostatic hyperplasia (BPH).
Conditions
- Overactive Bladder
- Urinary Urgency Incontinence
- Benign Prostatic Hyperplasia
- Prostate Cancer
- Prostatectomy
- Urinary Frequency
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Axonics SNM System | To assess clinical outcomes of the Axonics SNM System in the male OAB population. |
Timeline
- Start date
- 2024-10-22
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2024-07-19
- Last updated
- 2026-04-15
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06511141. Inclusion in this directory is not an endorsement.